CVT-303 |
RANEXA |
RS-43285-003 |
RANOLAZINE |
RANEXA® |
N-(2,6-DIMETHYLPHENYL)-2-[4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]PIPERAZIN-1-YL]ACETAMIDE |
RS-43285 |
drugbank:00243 |
pubchem.compound:56959 |
chembl:CHEMBL1404 |
rxcui:35829 |
chemidplus:95635-55-5 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antiallergy agent |
Year of Approval | 2006 |
Drug Class | antianginal agents |
Drug Categories | acetamides |
Drug Categories | antianginal agents |
Drug Categories | bsep/abcb11 substrates |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2d6 substrates |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | mate 1 inhibitors |
Drug Categories | mate 2 inhibitors |
Drug Categories | mate inhibitors |
Drug Categories | moderate risk qtc-prolonging agents |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | qtc prolonging agents |
Drug Categories | vasodilating agents |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Ranexa |
Novel drug target | Established target |
Mechanism of Interaction | Sodium channel protein type V alpha subunit blocker |
inhibitor (inhibitory) |
Trial Name | Ranexa |
Novel drug target | Established target |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel protein type IV alpha subunit blocker |
Direct Interaction | yes |
95635-55-5 | CAS Number |
Ranexa | Drug Brand |
CHEMBL1404 | ChEMBL ID |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Class | antianginal agents |
Year of Approval | 2006 |
Drug Indications | antiallergy agent |
Drug Class | Small Molecule |
FDA Approval | approved |
D03HYQ | TTD Drug ID |